Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
inhalation solution delivered by the Respimat® inhaler for four weeks in patients with
asthma. The selection of the optimum dose(s) will be based on bronchodilator efficacy (how
well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount
of the medication found in your blood).